BMEA Biomea Fusion, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1840439 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY76.7%
TTM EPS YoY95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-192.3%
ROA-53.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets73.0%
Debt / equity0.00x
Current ratio2.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.98x
Accruals ratio52.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $8.53M | $9.14M | $9.12M | $8.12M | $14.40M | $16.57M | $22.90M | $25.24M |
| SG&A expense | $4.43M | $3.62M | $3.65M | $3.60M | $4.20M | $4.71M | $6.82M | $4.83M |
| Operating income | -$12.96M | -$12.77M | -$12.77M | -$11.72M | -$20.80M | -$21.28M | -$29.71M | -$30.07M |
| Net income | -$6.18M | -$8.33M | -$12.41M | $4.61M | -$16.41M | -$20.74M | -$29.26M | -$29.30M |
| EBITDA | -$12.95M | -$12.75M | -$12.73M | -$11.67M | -$20.41M | -$20.78M | -$29.24M | -$29.61M |
| EPS (basic) | -0.09 | -0.12 | -0.17 | — | -0.27 | -0.51 | -0.80 | -0.81 |
| EPS (diluted) | -0.09 | -0.12 | -0.17 | — | -0.27 | -0.51 | -0.80 | -0.81 |
| Weighted avg. shares (diluted) | 72.59M | 72.36M | 72.30M | — | 59.85M | 40.63M | 36.63M | 36.27M |
| Banking | ||||||||
| Net interest income | $267,000 | $319,000 | $430,000 | -$3.53M | $526,000 | $309,000 | $450,000 | $772,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $26.40M | $34.82M | $44.69M | $55.81M | $46.64M | $56.22M | $35.86M | $58.65M |
| Current assets | $27.66M | $36.43M | $46.32M | $58.05M | $49.44M | $64.66M | $44.69M | $68.33M |
| PP&E, net | $37,000 | $47,000 | $47,000 | $153,000 | $200,000 | $2.83M | $3.30M | $3.77M |
| Total assets | $28.10M | $36.87M | $46.38M | $58.57M | $55.19M | $73.16M | $55.05M | $79.94M |
| Current liabilities | $12.77M | $10.48M | $9.29M | $11.10M | $15.56M | $17.57M | $19.82M | $21.67M |
| Total liabilities | $20.51M | $24.74M | $27.67M | $29.02M | $39.57M | $45.65M | $26.32M | $28.36M |
| Shareholders' equity | $7.59M | $12.14M | $18.72M | $29.55M | $15.62M | $27.51M | $28.74M | $51.57M |
| Shares outstanding | 72.68M | 72.48M | 72.30M | 72.30M | 59.51M | 58.13M | 37.57M | 36.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.43M | -$10.03M | -$11.67M | -$13.94M | -$11.55M | -$19.21M | -$25.67M | -$30.00M |
| Capital expenditure | — | — | — | — | $0 | $0 | $0 | $82,000 |
| Free cash flow | — | — | — | — | -$11.55M | -$19.21M | -$25.67M | -$30.09M |
| Investing cash flow | $0 | $0 | $550,000 | — | $0 | $0 | $0 | -$82,000 |
| Financing cash flow | $12,000 | — | — | $23.11M | $1.97M | $39.57M | $3.25M | $413,000 |
| Depreciation & amortization | $10,000 | $20,000 | $46,000 | $47,000 | $400,000 | $500,000 | $468,000 | $469,000 |
| Stock-based compensation | $1.62M | $1.59M | $1.58M | $1.84M | $1.94M | $2.57M | $3.17M | $4.49M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.